Samin Sharma, MD
Interventional Cardiology · New York, NYNPI 1376572933
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (49.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 71.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $68,447 and has fallen 68.7% since, to $21,424 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $2048.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$207K
- Medtronic$49K
- Cardiovascular Systems Inc.$19K
- Abbott$15K
- Edwards Lifesciences$145
- Shockwave Medical, Inc$120
- plus $302 from 8 others
Across 493 payments — averaging $6928.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$1M
- Medtronic$904K
- Boston Scientific$830K
- Abbott$270K
- Magenta Medical Inc$200K
- Shockwave Medical, Inc$107K
- plus $77K from 3 others
What the payments were for
- Consulting fees$3,2001%
- Speaking & faculty fees$131,51945%
- Grants$145,00050%
- Travel & lodging$7,7233%
- Food & beverage$3,4701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 39 | $207,093 |
| Medtronic(2 entities) | 22 | $48,735 |
| Cardiovascular Systems Inc. | 15 | $19,314 |
| Abbott | 50 | $15,204 |
| Edwards Lifesciences | 4 | $145 |
| Shockwave Medical, Inc | 2 | $120 |
| Bracco Diagnostics Inc. | 2 | $77 |
| Novo Nordisk | 1 | $72 |
| Acist Medical Systems, Inc. | 2 | $35 |
| Recor Medical Inc | 1 | $27 |
| Abiomed | 1 | $27 |
| Cardiva Medical, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ATHERECTOMY$65,000
- SYNERGY$21,202
- GENERAL - THERAPIES$17,511
- Coronary Orbital Atherectomy System$16,650
- GENERAL VASCULAR ACCESS$11,438
- GENERAL - STENTS$10,000
- Xience V coronary stent system$9,446
- CoreValve Evolut$8,180
- ROTABLATOR$5,438
- Dragonfly OCT$4,000
- ROTAPRO$2,827
- ROTAWIRE$2,438
- Diamondback Coronary$2,435
- Vitalyst$1,050
- MitraClip$566
- PRESSUREWIRE$150
- COREVALVE EVOLUT R$145
How this compares
$290,912 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 46 | $42,456 |
| EntrestoSacubitril/Valsartan | 26 | $37,526 |
| Praluent PenAlirocumab | 54 | $29,575 |
| EliquisApixaban | 26 | $25,454 |
| XareltoRivaroxaban | 14 | $16,801 |
| BrilintaTicagrelor | 16 | $12,806 |
| Prasugrel Hcl | 36 | $3,609 |
| Ranolazine ErRanolazine | 26 | $3,225 |
| Metoprolol Succinate | 155 | $2,512 |
| ClopidogrelClopidogrel Bisulfate | 124 | $1,796 |
| Atorvastatin Calcium | 103 | $1,161 |
| Pantoprazole Sodium | 37 | $684 |
| Rosuvastatin Calcium | 67 | $647 |
| Amlodipine Besylate | 68 | $614 |
| Ezetimibe | 11 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $23 | $37,52626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Torsten VahlNew York$280K
- George DangasNew York$263K
- Jeffrey MosesNew York$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.